Phibro Animal Health (NASDAQ:PAHC) Lowered to Hold Rating by StockNews.com

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Tuesday.

Other equities analysts have also recently issued research reports about the company. Morgan Stanley boosted their price target on Phibro Animal Health from $20.00 to $25.00 and gave the stock an "equal weight" rating in a report on Tuesday, December 17th. Barclays lifted their target price on Phibro Animal Health from $20.00 to $22.00 and gave the company an "underweight" rating in a research report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating and three have issued a hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $21.00.

Phibro Animal Health Price Performance

PAHC traded down $0.22 on Tuesday, hitting $21.46. 162,158 shares of the stock were exchanged, compared to its average volume of 183,676. The company has a debt-to-equity ratio of 2.99, a current ratio of 3.20 and a quick ratio of 1.37. Phibro Animal Health has a 12 month low of $12.17 and a 12 month high of $26.55. The firm has a market capitalization of $869.19 million, a price-to-earnings ratio of 44.71, a PEG ratio of 0.45 and a beta of 0.58. The business has a 50-day moving average of $22.78 and a two-hundred day moving average of $22.66.

Remove Ads

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.40 by $0.14. Phibro Animal Health had a net margin of 1.75% and a return on equity of 25.35%. Sell-side analysts forecast that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Institutional Trading of Phibro Animal Health

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Phibro Animal Health by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 1,514,736 shares of the company's stock valued at $31,809,000 after buying an additional 20,604 shares during the last quarter. American Century Companies Inc. increased its position in Phibro Animal Health by 18.0% in the 4th quarter. American Century Companies Inc. now owns 635,599 shares of the company's stock valued at $13,348,000 after acquiring an additional 96,787 shares during the period. Nuveen Asset Management LLC raised its stake in shares of Phibro Animal Health by 21.4% during the fourth quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company's stock valued at $12,348,000 after acquiring an additional 103,618 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Phibro Animal Health by 1.9% during the fourth quarter. Renaissance Technologies LLC now owns 557,800 shares of the company's stock worth $11,714,000 after purchasing an additional 10,600 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Phibro Animal Health by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 515,979 shares of the company's stock worth $10,838,000 after purchasing an additional 8,510 shares during the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.